Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist

[1]  J. Faillie,et al.  Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study , 2023, Journal of clinical medicine.

[2]  B. Kaffenberger,et al.  Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases , 2023, Melanoma research.

[3]  Shenmin Zhang,et al.  Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. , 2023, Journal of American Academy of Dermatology.

[4]  K. Reynolds,et al.  Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction. , 2023, International journal of dermatology.

[5]  S. Keam.  Tremelimumab: First Approval , 2022, Drugs.

[6]  J. Grob,et al.  Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study , 2022, Annals of the Rheumatic Diseases.

[7]  A. Giobbie-Hurder,et al.  Impact of Biologic Therapy on Cancer Outcomes in Patients with Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid. , 2022, Journal of the American Academy of Dermatology.

[8]  E. Giroux-Leprieur,et al.  Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report , 2022, Thoracic cancer.

[9]  K. Reynolds,et al.  Evaluating patterns of co-occurrence between cutaneous and non-cutaneous immune-related adverse events after immune checkpoint inhibitor therapy. , 2022, Journal of American Academy of Dermatology.

[10]  C. Nelson,et al.  Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors. , 2022, JAMA dermatology.

[11]  N. LeBoeuf,et al.  Treatment of Immune Checkpoint Inhibitor-Mediated Psoriasis: A Systematic Review. , 2022, Journal of the American Academy of Dermatology.

[12]  S. Ha,et al.  Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy , 2022, Immune network.

[13]  S. Divito,et al.  Updates and Insights in the Diagnosis and Management of DRESS Syndrome , 2021, Current Dermatology Reports.

[14]  Yuan Ji,et al.  Nivolumab-associated DRESS in a genetic susceptible individual , 2021, Journal for ImmunoTherapy of Cancer.

[15]  R. Sullivan,et al.  Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy , 2021, Clinical Cancer Research.

[16]  Douglas B. Johnson,et al.  Cutaneous adverse events caused by immune checkpoint inhibitors. , 2021, Journal of the American Academy of Dermatology.

[17]  P. Chou,et al.  Acute generalized exanthematous pustulosis induced by atezolizumab in a patient with lung adenocarcinoma. , 2021, Lung cancer.

[18]  K. Reynolds,et al.  Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis. , 2021, Journal of the American Academy of Dermatology.

[19]  J. Said,et al.  Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. , 2021, JAMA dermatology.

[20]  Kun‐Hsing Yu,et al.  Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA , 2021, Journal for ImmunoTherapy of Cancer.

[21]  Li Zhang,et al.  Immune checkpoint inhibitor-related epidermal necrolysis: A rare condition with poor prognosis. , 2021, European journal of cancer.

[22]  D. Bender,et al.  Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease , 2020, Journal for ImmunoTherapy of Cancer.

[23]  S. Rai,et al.  Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[24]  C. Lian,et al.  De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis. , 2020, Journal of the American Academy of Dermatology.

[25]  C. Porta,et al.  The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? , 2020, Frontiers in Immunology.

[26]  S. Singer,et al.  De novo subacute cutaneous lupus erythematosus‐like eruptions in the setting of programmed death‐1 or programmed death ligand‐1 inhibitor therapy: clinicopathological correlation , 2020, Clinical and experimental dermatology.

[27]  R. Gniadecki,et al.  Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management , 2020, Journal of cutaneous medicine and surgery.

[28]  I. Tattersall,et al.  Cutaneous immune-related adverse events to checkpoint inhibitors. , 2020, Clinics in dermatology.

[29]  M. Lacouture,et al.  CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. , 2020, Journal of the American Academy of Dermatology.

[30]  W. Xu,et al.  Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. , 2020, Journal of the National Cancer Institute.

[31]  K. Reynolds,et al.  Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series. , 2020, Journal of the American Academy of Dermatology.

[32]  R. Garje,et al.  Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence , 2020, Cancers.

[33]  C. Nelson,et al.  Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes. , 2020, Journal of the American Academy of Dermatology.

[34]  H. Uchi,et al.  Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma. , 2019, Clinical lung cancer.

[35]  C. Nelson,et al.  Nonbullous pemphigoid secondary to PD-1 inhibition , 2019, JAAD case reports.

[36]  R. Motzer,et al.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Ko,et al.  Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single‐institution retrospective analysis with stratification of reactions by toxicity and implications for management , 2019, Journal of the American Academy of Dermatology.

[38]  J. Callen,et al.  Nivolumab-induced lichen planus pemphigoides. , 2019, Cutis.

[39]  T. Thuraisingam,et al.  Nivolumab-associated DRESS syndrome: A case report , 2019, JAAD case reports.

[40]  W. Faridi,et al.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  J. Berk-Krauss,et al.  Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy , 2018, Journal of the American Academy of Dermatology.

[42]  W. Horninger,et al.  Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report , 2018, Urology case reports.

[43]  J. Sosman,et al.  Immune Checkpoint Inhibitor Toxicity in 2018 , 2018, JAMA.

[44]  M. Saha,et al.  Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma , 2018, JRSM open.

[45]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  C. Prost-Squarcioni,et al.  Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature , 2018, Front. Med..

[47]  Gregory Riely,et al.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Carlino,et al.  Immune Checkpoint Inhibitor Toxicity , 2018, Current Oncology Reports.

[49]  B. Schilling,et al.  Pembrolizumab‐associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma , 2018, The British journal of dermatology.

[50]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[51]  N. Yawalkar,et al.  Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[52]  S. Fatima,et al.  Severe recalcitrant morbilliform eruption from dual immune checkpoint blockade , 2018, JAAD case reports.

[53]  L. Geskin,et al.  A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors , 2018, International journal of dermatology.

[54]  Shun-Fa Yang,et al.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies , 2018, Cancer management and research.

[55]  J. Radford,et al.  Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma , 2018, JAAD case reports.

[56]  S. Aiba,et al.  Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab , 2018, Case Reports in Oncology.

[57]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[58]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[59]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[60]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[61]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[62]  Peng-fei Wang,et al.  Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis , 2017, Front. Pharmacol..

[63]  R. Motzer,et al.  Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[64]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  S. Granter,et al.  Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. , 2017, JAMA dermatology.

[66]  S. Nanjappa,et al.  Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome , 2017, Melanoma research.

[67]  Q. Ng,et al.  Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. , 2017, European journal of cancer.

[68]  F. Samie,et al.  Cutaneous adverse effects of the immune checkpoint inhibitors. , 2017, Current problems in cancer.

[69]  J. Wargo,et al.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.

[70]  M. Tetzlaff,et al.  Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. , 2017, The American Journal of dermatopathology.

[71]  J. Messina,et al.  Epidermal programmed cell death‐ligand 1 expression in TEN associated with nivolumab therapy , 2017, Journal of cutaneous pathology.

[72]  V. Vishwanath,et al.  Hemophagocytic Lymphohistiocytosis: A Diagnostic Conundrum , 2017, Journal of pediatric neurosciences.

[73]  D. Yanes,et al.  Inverse lichenoid drug eruption associated with nivolumab , 2016, JAAD case reports.

[74]  S. Gettinger,et al.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. , 2016, JAMA dermatology.

[75]  K. Mertz,et al.  Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy , 2016, Journal of Immunotherapy for Cancer.

[76]  Raghwa N. Sharma,et al.  Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. , 2016, Melanoma research.

[77]  P. Dziewulski,et al.  UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[78]  P. Dziewulski,et al.  U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.

[79]  S. Silva,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). , 2016, Revista da Associacao Medica Brasileira.

[80]  R. Novoa,et al.  Immunohistochemical analysis of lichenoid reactions in patients treated with anti‐PD‐L1 and anti‐PD‐1 therapy , 2016, Journal of cutaneous pathology.

[81]  K. Byth,et al.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.

[82]  J. Wolchok,et al.  Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 , 2016, Cancer Immunology Research.

[83]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[84]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[85]  R. Schwartz,et al.  Acute generalized exanthematous pustulosis (AGEP): A review and update. , 2015, Journal of the American Academy of Dermatology.

[86]  J. Roujeau,et al.  Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study , 2015, The British journal of dermatology.

[87]  M. Postow.  Managing immune checkpoint-blocking antibody side effects. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[88]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Lijuan Huang,et al.  The PD-1/PD-Ls pathway and autoimmune diseases. , 2014, Cellular immunology.

[90]  A. López-Guillermo,et al.  Adult haemophagocytic syndrome , 2014, The Lancet.

[91]  L. Naldi,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study , 2013, The British journal of dermatology.

[92]  M. Lacouture,et al.  The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. , 2013, Journal of the American Academy of Dermatology.

[93]  C. Berking,et al.  The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.

[94]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  S. Ugurel,et al.  Cutaneous side effects of new antitumor drugs: clinical features and management. , 2012, Deutsches Arzteblatt international.

[96]  S. Halevy,et al.  The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases , 2010, The British journal of dermatology.

[97]  M. Britschgi,et al.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis. , 2001, The Journal of clinical investigation.

[98]  Emily Coleman,et al.  The life-threatening eruptions of immune checkpoint inhibitor therapy. , 2020, Clinics in dermatology.

[99]  S. Cascinu,et al.  Stevens-Johnson syndrome during nivolumab treatment of NSCLC. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  Abhishek De,et al.  Acute Generalised Exanthematous Pustulosis: An Update , 2018, Indian journal of dermatology.

[101]  Omar Pacha,et al.  Skin Reactions to Immune Checkpoint Inhibitors. , 2017, Advances in experimental medicine and biology.

[102]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..